INT236711
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
Cases with neither BCL-2 or BCL-6 rearrangements compromise the third genetic group of DLBCL. | |||||||||||||||
| |||||||||||||||
|
Relative gene expression of four genes (Bcl6, Traf2 binding protein, heat shock protein 1B, and Cytochrome P450) was measured by qRTPCR. | |||||||||||||||
| |||||||||||||||
|
The antigen profile includes CD20, CD19 and CD5 positive, and is BCL-2 and cyclin D1 positive but usually CD10 and BCL-6 negative. | |||||||||||||||
| |||||||||||||||
|
Therefore, OME may be due to alterations in the mucosal epithelium due to inflammatory reactions in the adenoids, and may influence the expression of BCL-6, which controls antibody production in the germinal centers of adenoids. | |||||||||||||||
| |||||||||||||||
|
Since we measured BCL-6 expression only after antigen stimulation, and since BCL-6 staining occurred primarily in the germinal centers, it may be that this transcription factor directly controls IgA production in the germinal centers. | |||||||||||||||
| |||||||||||||||
|
In conclusion, we observed significant decreases in the respiratory epithelium of adenoid mucosa, significant increases of squamous epithelial metaplasia, and significant reductions of BCL-6 expression in OME patients. | |||||||||||||||
| |||||||||||||||
|
However, IgA secretion was not increased significantly in the OME group, and thus a firm association between IgA secretion and BCL-6 expression could not be made. | |||||||||||||||
| |||||||||||||||
|
BCL-6 was first discovered as a gene translocated in a type of non-Hodgkin's lymphoma, but it has not been found in terminally differentiated plasma cells.28,29 We found that BCL-6 expression was significantly lower in the OME group, and that it was expressed primarily in the germinal centers. | |||||||||||||||
| |||||||||||||||
|
These results suggest that increased squamous metaplasia and lower BCL-6 expression in adenoids may be associated with increased susceptibility to OME.
| |||||||||||||||
| |||||||||||||||
|
To determine the factors associated with OME in children, we evaluated adenoid size, mucosal barrier, squamous changes in ciliated epithelium, IgA secretion, and expression of B cell leukemia lymphoma-6 (BCL-6) in children with and without OME.
| |||||||||||||||
| |||||||||||||||
|
One explanation might be that BCL-6 suppresses conversion of B lymphocytes to plasma cells in normal adenoids, but decreased BCL-6 expression during infection allows increased conversion to plasma cells and thus greater production of immunoglobulin. | |||||||||||||||
| |||||||||||||||
|
To determine the factors associated with this condition, we evaluated adenoid size, mucosal barrier, squamous changes of ciliated epithelium, IgA secretion, and BCL-6 expression in adenoids.
| |||||||||||||||
| |||||||||||||||
|
The OME group showed greater incidence of squamous metaplasia, fewer ciliated cells, and lower expression of BCL-6 (p < 0.05 each). | |||||||||||||||
| |||||||||||||||
|
The adenoids were also stained with cytokeratin to evaluate mucosal barriers, and with anti-IgA antibody and anti- BCL-6 antibody to determine expression of IgA and BCL-6.
| |||||||||||||||
| |||||||||||||||
|
corepressors, such as B-cell lymphoma 6 (BCL-6), silencing mediator for | |||||||||||||||
| |||||||||||||||
|
BCL-6 is overexpressed in 40% of diffuse large B-cell lymphomas (Pasqualucci et al. 2003). | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.